Skip to content
Investing

MDA Space Investor Profile: Satellite Factories, Space Robotics and Two Pending Deals

What MDA Space makes, how its three divisions performed in the third quarter, how much cash it holds after this year's US listing, and the launches, deals and risks to watch into 2027.

UK Science Secretary Peter Kyle listens to a woman at the MDA Space stand, its logo on the wall behind, at the 2024 Farnborough Airshow.
Photo: Alecsandra Dragoi / Department for Science, Innovation and Technology, via Wikimedia Commons, CC BY 2.0

MDA Space builds satellites, antennas, space robotics and Earth observation services from bases in Canada, the US and the UK. After raising more than C$1.5 billion in new equity this year it holds C$1.33 billion of net cash, has lifted its 2026 guidance and is waiting to close two acquisitions that will absorb much of that money.

What MDA Space does

Founded in 1969, MDA Space describes itself as Canada's largest space technology developer and manufacturer, with more than 450 missions behind it. Its shares trade in Toronto under the symbol MDA and, since a US initial public offering that closed in March 2026, on the New York Stock Exchange.

The business is split into three areas. Satellite Systems designs and builds whole satellites and payloads, including its MDA AURORA software-defined satellite, and is building the satellites for Telesat Lightspeed, a broadband constellation in low Earth orbit. In August the value of that contract rose by C$474 million when Telesat enlarged the constellation. MDA opened a high-volume satellite manufacturing facility in Montréal in May and has launched the first satellites it built for Globalstar's existing constellation.

Geointelligence sells Earth observation data, analytics and related services. Its next-generation Earth observation constellation, MDA CHORUS, is due to launch around the end of 2026, and in May MDA said it had 41 early customer contracts and letters of interest for its data. Robotics and Space Operations builds robotic systems such as Canadarm3 for lunar exploration.

Defence is a growing focus. This year MDA set up 49North, a Canadian defence business, and unveiled MDA MIDNIGHT, a space control platform, and MDA AURORA BLACK, a defence-focused version of its satellite.

MDA Space: share price, chart and news

The latest numbers

In the third quarter of 2026 revenue rose 21.5% to C$498.1 million and adjusted EBITDA grew 15.9% to C$96.0 million, a margin of 19.3%. Over the first nine months revenue reached C$1.46 billion, up 28.8%.

DivisionQ3 2026 revenueQ3 2025 revenueChange
Satellite SystemsC$358.3mC$283.5m+26.4%
Robotics and Space OperationsC$79.9mC$78.3m+2.0%
GeointelligenceC$59.9mC$48.0m+24.8%
TotalC$498.1mC$409.8m+21.5%

Net income for the quarter was C$30.9 million, or C$0.19 a diluted share, against C$27.0 million, or C$0.21, a year earlier. Adjusted diluted earnings per share were flat at C$0.37, and C$1.11 for the nine months against C$1.05. Operating cash flow was C$106.2 million and free cash flow C$61.6 million.

On 5 November MDA raised its 2026 guidance to revenue of C$1.90 billion to C$1.95 billion and adjusted EBITDA of C$355 million to C$375 million. It kept its margin target of 18% to 20% and capital spending of C$225 million to C$275 million, and still expects full-year free cash flow to be neutral to negative.

Balance sheet at 30 September 2026

  • C$2.15bn cash
  • C$825.8m long-term debt
  • C$3.95bn order backlog

Cash, shares and acquisitions

Net cash of C$1.33 billion compares with net debt of C$120 million at the end of 2025. Total liquidity was about C$2.9 billion. The money came from the March US offering, a bought deal of common shares in July and C$600 million of senior unsecured notes due 2033 that closed in August. Net proceeds from share issues totalled C$1.55 billion over the first nine months.

The new shares have diluted existing holders. The diluted weighted share count was 163.1 million in the third quarter, against 130.1 million a year earlier, which is why earnings per share have lagged profit growth. In September the Toronto Stock Exchange approved a normal course issuer bid, which allows the company to buy back shares.

Two deals are pending. MDA agreed in June to pay US$620 million in cash for Blue Canyon Technologies, a Denver-based spacecraft maker that is part of RTX's Raytheon business, with closing expected by the end of 2026. In July it made a firm offer of about €567 million for roughly 70% of CLS, the Toulouse satellite data group in which the French space agency CNES keeps about 30%. CLS expects about €286 million of revenue in 2026, and closing is expected at the end of 2026 or early in 2027. MDA has said it targets net debt of 1.5 to 2.5 times adjusted EBITDA once the deals are done.

Backlog has drifted lower as large programmes are worked down: C$3.95 billion at the end of September against C$4.01 billion at the end of 2025. Third-quarter bookings were C$444.2 million. An authorisation worth more than C$100 million for antennas on Europe's IRIS² constellation, signed with Thales Alenia Space on 30 October, will be added to backlog in the fourth quarter.

The main risks

Risks MDA itself flags

  • Fixed-price contracts, where cost overruns fall on the company
  • Dependence on a small number of large customers and programmes, led by Telesat Lightspeed
  • Launch schedule delays, including for MDA CHORUS, and the loss or degradation of the RADARSAT-2 satellite
  • Government policy and funding, export controls, tariffs and trade disputes
  • Completing and integrating the Blue Canyon and CLS acquisitions, and the financing and covenant terms that come with more debt

Canadarm3 shows how policy can shift. In August, according to MDA, the Canadian Space Agency said it plans to repurpose its Canadarm3 investments towards the next phase of lunar exploration. Robotics revenue still grew slightly in the third quarter on steady Canadarm3 work, and MDA's response did not put a figure on any financial effect.

The gross margin also narrowed to 25.3% from 26.4% in the third quarter because of programme mix, a reminder that faster growth does not automatically mean higher margins.

What to watch next

EventTiming
Launch of the MDA CHORUS constellationOn schedule for the end of 2026, per the company
Blue Canyon Technologies acquisition closesExpected by the end of 2026
IRIS² authorisation added to backlogFourth quarter of 2026
CLS acquisition closesEnd of 2026 or early 2027
Fourth-quarter and full-year 2026 resultsEarly 2027; date not yet announced (2025 results came on 4 March 2026)

Investors will also look for a definitive IRIS² contract, further Telesat Lightspeed milestones and whether orders keep pace with revenue now that backlog is below C$4 billion.

Sources

Related stories

Markets

MDA Space Raises Its 2026 Outlook as Third-Quarter Revenue Climbs 21.5%

The Canadian satellite maker now expects up to C$1.95bn of 2026 revenue after Telesat Lightspeed work lifted quarterly sales to C$498.1m and new orders more than doubled.

Investing

Planet Labs Profile: The Satellite Imaging Firm Riding Europe's Defence Spending

Planet Labs images the Earth daily and sells data and dedicated satellites to governments. Revenue is up more than 50%, but losses, share sales and lumpy deliveries remain risks.

Investing

Redwire Profile: Space Solar Arrays, Military Drones and a $620m Order Book

How Redwire earns its money from space solar arrays, spacecraft and military drones, what its third-quarter filing shows on backlog, cash and dilution, and what to watch into late…

Investing

BlackSky Technology Profile: The Real-Time Satellite Imaging Firm Turning Profitable

BlackSky Technology sells fast, high-resolution satellite imagery to defence customers. Revenue doubled last quarter, but debt, launch timing and government budgets remain key…

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…